| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Collagen Cross-Linked N-Telopeptide (NTx), 24-Hour Urine : 36421
Test CodeUNT24Q or 36421
Alias/See Also
Collagen Cross-Linked N-Telopeptide * Collagen Cross-Linked,24-Hour Urine * N-Telopeptide 24 hr Urine * Collagen Cross Links 24 hr ur * Collagen Crosslinks * Osteomark * Ostex * Type I Collagen
CPT Codes
82523, 82570
Includes
Includes Creatinine
Preferred Specimen
2 mL of a 24-hour urine collection
Minimum Volume
1 mL
Instructions
Do not include first morning specimen; collect all subsequent voidings. The last sample collected should be the first morning specimen voided the following morning at the same time as the previous morning's first voiding. Specify 24-hour total volume on container and test requisition
Transport Container
Plastic urine container
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Ambient: 72 hours
Refrigerated: 5 days
Frozen: 30 days
Refrigerated: 5 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Acidified specimen • Preserved specimen
Methodology
Chemiluminescence
Setup Schedule
Monday - Saturday
Report Available
1-2 days (From receipt at performing laboratory)
Limitations
Requires accurate 24-hour urine collection. Collagen Cross-Linked N-Telopeptide is affected by diurnal variation.
Reference Range
| Male 18-29 Years: 5-88 nM BCE/mM creat 30-39 Years: 7-51 nM BCE/mM creat 40-49 Years: 5-47 nM BCE/mM creat 50-60 Years: 6-43 nM BCE/mM creat Female Premenopausal: 5-79 nM BCE/mM creat Results are primarily used for monitoring the response to therapy. A value within the premenopausal reference range does not rule out osteoporosis nor the need for therapy. Creatinine, 24-Hour Urine < 3 years Not established 3-8 Years 0.10-0.80 g/24 h 9-12 Years 0.20-1.40 g/24 h 13-17 Years 0.40-1.90 g/24 h > 17 Years 0.50-2.15 g/24 h |
Clinical Significance
NTx is useful to assess bone resorption in patients with metabolic bone disease and monitor therapy to slow or halt osteoporotic bone loss. A decline of 30% or more of NTx over a six-month period suggests effective therapy.
Performing Laboratory
Quest Diagnostics
